Periodic Reporting for period 1 - EyeTREAT (Innovative tool for personalized treatment of patients with neovascular age-macular degeneration: dosage optimization for long term efficacy treatment)
Periodo di rendicontazione: 2018-09-01 al 2019-11-30
However, such pharmacokinetic-pharmacodynamic models are still missing. Combining population pharmacokinetic and optical coherence tomography (OCT) imaging technique is a new, novel and promising approach. The drug effect can be evaluated non-invasively, measuring the central macular thickness in the retina scan. In the present 15 month-project, preliminary models that link drug concentration in vitreous and effect on the decrease of the thickness on the central retina have been generated. The final models can allow
appropriate individualized dosing regimen to the patients in clinics that will be anticipated from individual retina scan determinations with OCT.
The optimization and personalization of dosing regimen will ensure an efficient long-lasting treatment, improving patient quality of life while reducing the burden to the health care system. Moreover, the models will increase our understanding in the treatments, constitute a pioneer tool in effect assessment in ocular therapeutic field and a first step towards more advanced ophthalmic models.
I have attended seven international and national conferences and meetings disseminating my research with oral presentation or poster. I have published four scientist articles, having one ready for submission related to new antiangiogenic drug. The results on the present clinical project related to Avastin drug (bevacizumab) is under elaboration.